Lucid Diagnostics (LUCD) to Release Quarterly Earnings on Thursday

Lucid Diagnostics (NASDAQ:LUCD) is anticipated to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Lucid Diagnostics to post earnings of ($0.07) per share and revenue of $1.3880 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 26, 2026 at 8:30 AM ET.

Lucid Diagnostics Price Performance

Lucid Diagnostics stock opened at $1.20 on Wednesday. The company has a market cap of $165.22 million, a price-to-earnings ratio of -1.15 and a beta of 1.18. The firm has a 50-day moving average of $1.30 and a 200-day moving average of $1.18. Lucid Diagnostics has a one year low of $0.95 and a one year high of $1.80.

Institutional Trading of Lucid Diagnostics

A number of hedge funds have recently made changes to their positions in the business. Centiva Capital LP acquired a new position in shares of Lucid Diagnostics during the 3rd quarter worth approximately $25,000. Abel Hall LLC acquired a new position in shares of Lucid Diagnostics in the fourth quarter valued at $33,000. JPMorgan Chase & Co. increased its holdings in shares of Lucid Diagnostics by 71,026.1% in the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock valued at $38,000 after purchasing an additional 32,672 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Lucid Diagnostics in the first quarter valued at about $39,000. Finally, Invesco Ltd. acquired a new stake in shares of Lucid Diagnostics during the 2nd quarter worth about $41,000. 74.01% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LUCD has been the subject of several recent research reports. Wall Street Zen cut Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Ascendiant Capital Markets increased their price objective on Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a report on Wednesday, December 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $3.94.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.